Journal of Modern Pharmacology and Pathology (JMPP) (ISSN 2707-8612)

More than a year into the COVID-19 pandemic, the battle has not yet been won in many fields and there may be difficult times ahead. However, the pre-existing health crisis is still problematic in the healthcare arena during the pandemic. Liver cancer is a disease that is notable for its high global incidence and mortality rates, and there is an ongoing search for a cure for liver cancer cells.

A paper published in January this year in our Journal of Modern Pharmacology and Pathology (JMPP) (ISSN 2707-8612) : Comparison of the Efficacy, Immune Function and Survival Rate of Sorafenib and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma.

It explored some cure methods for hepatocellular carcinoma. The study has achieved fruitful results and has been included in our publication.

Journal of Modern Pharmacology and Pathology, published by Innovation Forever Publishing Group Limited, is a quarterly open access journal dedicated to providing researchers and readers in the fields of pharmacology, pathology and pathology with access to online academic journals and providing a platform for online scholarly communication between researchers and readers in the fields of pharmacology and pathology.

Choose us

We are the global peer-reviewed journal publisher with full open access, based on the spirit of openness. We are keen to cooperate with the global academic circles and promote open academic research to all over the world. We are committed to providing services for authors while strictly abiding by publishing standards and editorial credibility.

The target audience of JMPP includes researchers in pharmacology, pathology and other related specialties, clinicians at all levels, pharmacists, pharmaceutical scientists and technicians who are committed to the advancement of pharmacology.

We would like to thank all those who have helped the Journal to grow and we look forward to the research in pharmacology and pathology and its continued development. We welcome your enquiries and submissions. Last but not least, we do not charge publication fees, which is an advantage for the researcher.